[KR-바이오] 06/25 Korea Market Insights

Samsung Biologics is currently facing a critical juncture as its labor union initiates a vote to withdraw from the supra-corporate union, signaling a potential escalation in labor-management conflict. While the company continues to demonstrate strong operational momentum through its CRDMO capabilities and global expansion plans, internal instability poses a significant risk to organizational cohesion. The dispute over livelihood cost provisions and the push for an independent union suggest that management may face headwinds in maintaining labor peace, which could potentially impact long-term productivity and investor sentiment if the situation remains unresolved.

Celltrion’s recent strategic moves demonstrate a dual focus on financial stability and long-term R&D competitiveness. The issuance of Convertible Bonds (CB) by the holding company to increase its stake in Celltrion signals strong management confidence and a commitment to enhancing shareholder value through increased ownership. Simultaneously, the company’s aggressive pursuit of a ‘4-mechanism’ obesity treatment positions it to leapfrog current market leaders in the high-growth GLP-1 segment. By combining these financial maneuvers with global recognition as a top-tier global enterprise, Celltrion is effectively strengthening its market position and pipeline innovation, which should serve as a positive catalyst for institutional investor sentiment.

Yuhan Corporation is currently at a pivotal inflection point, transitioning from its centennial legacy to a future-oriented global innovative pharmaceutical powerhouse. While the company is celebrating its 100-year heritage through the opening of the ‘Willow House,’ the core investment thesis remains anchored in its robust R&D pipeline.

The recent designation of its Gaucher disease therapeutic candidate as an orphan drug in both the U.S. and Europe serves as a critical catalyst. This regulatory milestone significantly de-risks the development process and enhances the asset’s commercial viability in the high-margin rare disease market. Investors should monitor how this momentum translates into further global licensing deals and long-term earnings growth beyond its traditional domestic business.

Alteogen has reached a pivotal milestone by officially identifying Sanofi as the first licensee for its proprietary ALT-B4 (hyaluronidase) platform. This disclosure validates the commercial viability of its SC (Subcutaneous) formulation technology, which is increasingly becoming the industry standard for extending the lifecycle of blockbuster biologics. Furthermore, the company’s expansion into ADC (Antibody-Drug Conjugate) therapeutics, supported by promising preclinical data, signals a robust long-term growth trajectory beyond its core platform business. While there is ongoing debate regarding a potential KOSPI migration, the fundamental value remains anchored in the company’s ability to secure a dominant position in the global SC market through high-barrier-to-entry technology partnerships.

HLB is currently at a critical juncture as it awaits the (FDA approval) decision for its lead candidate, (Rivoceranib). While management is actively attempting to stabilize investor sentiment through (insider buying) and public assurances regarding the regulatory process, the stock remains highly sensitive to volatility and speculative noise.

The company’s strategic pivot toward expanding its pipeline into (CAR-T) and (FGFR2) therapies suggests a long-term vision to diversify beyond its flagship asset. However, recent setbacks concerning (patent registration) issues for its obesity drug candidate highlight potential operational risks in intellectual property management. Investors should maintain a cautious stance, prioritizing the outcome of the FDA review over short-term market fluctuations.